252 related articles for article (PubMed ID: 34275586)
21. A phase I study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas.
Den RB; Kamrava M; Sheng Z; Werner-Wasik M; Dougherty E; Marinucchi M; Lawrence YR; Hegarty S; Hyslop T; Andrews DW; Glass J; Friedman DP; Green MR; Camphausen K; Dicker AP
Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):321-8. PubMed ID: 22687197
[TBL] [Abstract][Full Text] [Related]
22. Comprehensive Analysis Reveals a 4-Gene Signature in Predicting Response to Temozolomide in Low-Grade Glioma Patients.
Wang Q; He Z; Chen Y
Cancer Control; 2019; 26(1):1073274819855118. PubMed ID: 31167546
[TBL] [Abstract][Full Text] [Related]
23. Extended-schedule dose-dense temozolomide in refractory gliomas.
Berrocal A; Perez Segura P; Gil M; Balaña C; Garcia Lopez J; Yaya R; Rodríguez J; Reynes G; Gallego O; Iglesias L;
J Neurooncol; 2010 Feb; 96(3):417-22. PubMed ID: 19669096
[TBL] [Abstract][Full Text] [Related]
24. Temozolomide in the treatment of recurrent malignant glioma in Chinese patients.
Chan DT; Poon WS; Chan YL; Ng HK
Hong Kong Med J; 2005 Dec; 11(6):452-6. PubMed ID: 16340021
[TBL] [Abstract][Full Text] [Related]
25. Predictive significance of mean apparent diffusion coefficient value for responsiveness of temozolomide-refractory malignant glioma to bevacizumab: preliminary report.
Nagane M; Kobayashi K; Tanaka M; Tsuchiya K; Shishido-Hara Y; Shimizu S; Shiokawa Y
Int J Clin Oncol; 2014 Feb; 19(1):16-23. PubMed ID: 23354833
[TBL] [Abstract][Full Text] [Related]
26. Improvement of health related quality of life in patients with recurrent glioma treated with bevacizumab plus daily temozolomide as the salvage therapy.
Liu Y; Feng F; Ji P; Liu B; Ge S; Yang C; Lou M; Liu J; Li B; Gao G; Qu Y; Wang L
Clin Neurol Neurosurg; 2018 Jun; 169():64-70. PubMed ID: 29631109
[TBL] [Abstract][Full Text] [Related]
27. Temozolomide for the treatment of recurrent supratentorial glioma: results of a compassionate use program in Belgium.
Everaert E; Neyns B; Joosens E; Strauven T; Branle F; Menten J
J Neurooncol; 2004 Oct; 70(1):37-48. PubMed ID: 15527106
[TBL] [Abstract][Full Text] [Related]
28. Prolonged administration of temozolomide in adult patients with anaplastic glioma.
Freyschlag CF; Smolczyk DR; Janzen E; Schmieder K; Thomé C; Lohr F; Wenz F; Weiss C; Tuettenberg J; Seiz M
Anticancer Res; 2011 Nov; 31(11):3873-7. PubMed ID: 22110212
[TBL] [Abstract][Full Text] [Related]
29. The efficacy and safety of various dose-dense regimens of temozolomide for recurrent high-grade glioma: a systematic review with meta-analysis.
Wei W; Chen X; Ma X; Wang D; Guo Z
J Neurooncol; 2015 Nov; 125(2):339-49. PubMed ID: 26334318
[TBL] [Abstract][Full Text] [Related]
30. Dose-dense temozolomide for recurrent high-grade gliomas: a single-center retrospective study.
Garcia CR; Slone SA; Morgan RM; Gruber L; Kumar SS; Lightner DD; Villano JL
Med Oncol; 2018 Aug; 35(10):136. PubMed ID: 30155806
[TBL] [Abstract][Full Text] [Related]
31. Phase II study of protracted daily temozolomide for low-grade gliomas in adults.
Kesari S; Schiff D; Drappatz J; LaFrankie D; Doherty L; Macklin EA; Muzikansky A; Santagata S; Ligon KL; Norden AD; Ciampa A; Bradshaw J; Levy B; Radakovic G; Ramakrishna N; Black PM; Wen PY
Clin Cancer Res; 2009 Jan; 15(1):330-7. PubMed ID: 19118062
[TBL] [Abstract][Full Text] [Related]
32. [Temozolomide in the treatment of recurrent malignant glioma].
Kobayashi H; Sawamura Y; Ishii N; Murata J; Iwasaki Y
No Shinkei Geka; 2006 Dec; 34(12):1241-7. PubMed ID: 17154070
[TBL] [Abstract][Full Text] [Related]
33. Temozolomide for recurrent or progressive high-grade malignant glioma: results of an Austrian multicenter observational study.
Hassler M; Micksche M; Stockhammer G; Pichler J; Payer F; Abuja B; Deinsberger R; Marosi C
Wien Klin Wochenschr; 2006 May; 118(7-8):230-8. PubMed ID: 16794761
[TBL] [Abstract][Full Text] [Related]
34. A prospective phase II single-institution trial of sunitinib for recurrent malignant glioma.
Pan E; Yu D; Yue B; Potthast L; Chowdhary S; Smith P; Chamberlain M
J Neurooncol; 2012 Oct; 110(1):111-8. PubMed ID: 22832897
[TBL] [Abstract][Full Text] [Related]
35. Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status.
Groves MD; Puduvalli VK; Conrad CA; Gilbert MR; Yung WK; Jaeckle K; Liu V; Hess KR; Aldape KD; Levin VA
J Neurooncol; 2006 Oct; 80(1):83-90. PubMed ID: 16639492
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and toxicity of postoperative temozolomide radiochemotherapy in malignant glioma.
Kocher M; Kunze S; Eich HT; Semrau R; Müller RP
Strahlenther Onkol; 2005 Mar; 181(3):157-63. PubMed ID: 15756519
[TBL] [Abstract][Full Text] [Related]
37. A phase II study of extended low-dose temozolomide in recurrent malignant gliomas.
Khan RB; Raizer JJ; Malkin MG; Bazylewicz KA; Abrey LE
Neuro Oncol; 2002 Jan; 4(1):39-43. PubMed ID: 11772431
[TBL] [Abstract][Full Text] [Related]
38. A case series of salvage CCNU in high-grade glioma who have previously received temozolomide from a tertiary care institute in Mumbai.
Patil VM; Abhinav R; Tonse R; Epari S; Gupta T; Jalali R
Indian J Cancer; 2016; 53(4):558-561. PubMed ID: 28485350
[TBL] [Abstract][Full Text] [Related]
39. When temozolomide alone fails: adding procarbazine in salvage therapy of glioma.
Huang F; Kavan P; Guiot MC; Markovic Y; Roberge D
Can J Neurol Sci; 2008 May; 35(2):192-7. PubMed ID: 18574933
[TBL] [Abstract][Full Text] [Related]
40. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.
Perry JR; Bélanger K; Mason WP; Fulton D; Kavan P; Easaw J; Shields C; Kirby S; Macdonald DR; Eisenstat DD; Thiessen B; Forsyth P; Pouliot JF
J Clin Oncol; 2010 Apr; 28(12):2051-7. PubMed ID: 20308655
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
